Unknown

Dataset Information

0

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial.


ABSTRACT: BACKGROUND:Oral CXC chemokine receptor 2 (CXCR2) antagonists have been shown to inhibit neutrophil migration and activation in the lung in preclinical and human models of neutrophilic airway inflammation. A previous study with danirixin, a reversible CXCR2 antagonist, demonstrated a trend for improved respiratory symptoms and health status in patients with COPD. METHODS:This 26-week, randomised, double-blind, placebo-controlled phase IIb study enrolled symptomatic patients with mild-to-moderate COPD at risk for exacerbations. Patients received danirixin 5, 10, 25, 35 or 50?mg twice daily or placebo in addition to standard of care. Primary end-points were the dose response of danirixin compared with placebo on the incidence and severity of respiratory symptoms (Evaluating Respiratory Symptoms in COPD [E-RS:COPD] scores) and safety. Secondary end-points included the incidence of moderate-severe exacerbations, health status (COPD Assessment test, CAT) and health-related quality of life HRQoL (St. George Respiratory Questionnaire-COPD, SGRQ-C). RESULTS:A total of 614 participants were randomized to treatment. There were no improvements in E-RS:COPD, CAT or SGRQ-C scores in participants treated with any dose of danirixin compared to placebo; a larger than expected placebo effect was observed. There was an increased incidence of exacerbation in the danirixin-treated groups and an increased number of pneumonias in participants treated with danirixin 50?mg. CONCLUSIONS:The robust placebo and study effects prohibited any conclusions on the efficacy of danirixin. However, the absence of a clear efficacy benefit and the observed increase in exacerbations in danirixin-treated groups suggests an unfavorable benefit-risk profile in patients with COPD. TRIAL REGISTRATION:This study was registered with clinicaltrials.gov, NCT03034967.

SUBMITTER: Lazaar AL 

PROVIDER: S-EPMC7291447 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

altmetric image

Publications

CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: a phase 2b trial.

Lazaar Aili L AL   Miller Bruce E BE   Donald Alison C AC   Keeley Thomas T   Ambery Claire C   Russell John J   Watz Henrik H   Tal-Singer Ruth R  

Respiratory research 20200612 1


<h4>Background</h4>Oral CXC chemokine receptor 2 (CXCR2) antagonists have been shown to inhibit neutrophil migration and activation in the lung in preclinical and human models of neutrophilic airway inflammation. A previous study with danirixin, a reversible CXCR2 antagonist, demonstrated a trend for improved respiratory symptoms and health status in patients with COPD.<h4>Methods</h4>This 26-week, randomised, double-blind, placebo-controlled phase IIb study enrolled symptomatic patients with mi  ...[more]

Similar Datasets

| S-EPMC10623880 | biostudies-literature
| S-EPMC3257955 | biostudies-literature
| S-EPMC3979657 | biostudies-literature
| S-EPMC6360623 | biostudies-literature
| S-EPMC7568676 | biostudies-literature
| S-EPMC8842394 | biostudies-literature
| S-EPMC10201404 | biostudies-literature
2003-07-16 | GSE475 | GEO
| S-EPMC4498483 | biostudies-literature
2014-08-14 | E-GEOD-60399 | biostudies-arrayexpress